CareMax Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat CareMax de winst en omzet met respectievelijk 77.2% en 26% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 101.9% per jaar.

Belangrijke informatie

77.2%

Groei van de winst

101.9%

Groei van de winst per aandeel

Healthcare winstgroei	21.0%
Inkomstengroei	26.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Aug 14

Recent updates

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Aug 14

CareMax, Inc.'s (NASDAQ:CMAX) Subdued P/S Might Signal An Opportunity

Jun 20

Here's What Analysts Are Forecasting For CareMax, Inc. (NASDAQ:CMAX) After Its First-Quarter Results

May 13

Analysts Have Just Cut Their CareMax, Inc. (NASDAQ:CMAX) Revenue Estimates By 11%

Mar 11

CareMax: Numbers Are Strong, Compelling Value On Offer

Sep 16

CareMax GAAP EPS of -$0.11 misses by $0.09, revenue of $172.28M beats by $36.85M

Aug 09

CareMax: Steward Health Care Acquisition Highlights Growth Ambitions

Jul 02

Winst- en omzetgroeiprognoses

OTCPK:CMAX.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1,383	-72	N/A	N/A	1
12/31/2025	1,240	-151	N/A	N/A	1
12/31/2024	772	-130	N/A	N/A	1
6/30/2024	785	-783	-62	-52	N/A
3/31/2024	810	-645	-61	-49	N/A
12/31/2023	751	-683	-62	-47	N/A
9/30/2023	764	-207	-101	-91	N/A
6/30/2023	719	-126	-94	-84	N/A
3/31/2023	667	-103	-86	-78	N/A
12/31/2022	631	-38	-76	-68	N/A
9/30/2022	585	-52	-61	-55	N/A
6/30/2022	532	-44	-54	-48	N/A
3/31/2022	405	-25	-43	-39	N/A
12/31/2021	296	-7	-28	-24	N/A
9/30/2021	206	-2	-13	-9	N/A
6/30/2021	125	12	-4	-2	N/A
3/31/2021	106	6	5	7	N/A
12/31/2020	103	8	3	5	N/A
9/30/2020	101	7	5	8	N/A
12/31/2019	91	6	6	7	N/A
12/31/2018	72	3	0	1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CMAX.Q de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CMAX.Q de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CMAX.Q de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CMAX.Q ( 26% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CMAX.Q ( 26% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CMAX.Q naar verwachting over 3 jaar hoog zal zijn

CareMax Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 125%, revenue upgraded

Consensus EPS estimates upgraded to US$20.83 loss, revenue downgraded

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Consensus EPS estimates upgraded to US$33.26 loss

Price target decreased by 42% to US$26.00

Price target decreased by 17% to US$37.33

Recent updates

CareMax, Inc.(OTCPK:CMAX.Q) dropped from NASDAQ Composite Index

CareMax, Inc.(NasdaqGS:CMAX) dropped from S&P TMI Index

Interim DIP Financing Approved for CareMax, Inc.

Interim DIP Financing Approved for CareMax, Inc.

CareMax, Inc. Filed for Bankruptcy

CareMax, Inc. announced delayed 10-Q filing

Consensus EPS estimates fall by 125%, revenue upgraded

High number of new directors

CareMax Receives Non-Compliance Notice from Nasdaq Regarding Minimum MVPHS Requirement

Consensus EPS estimates upgraded to US$20.83 loss, revenue downgraded

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$33.26 loss

New major risk - Financial position

High number of new directors

CareMax, Inc. announced delayed annual 10-K filing

Price target decreased by 42% to US$26.00

Price target decreased by 17% to US$37.33

CareMax Announces 1-for-30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

CareMax Receives Non-Compliance Notice From Nasdaq

New major risk - Share price stability

New minor risk - Market cap size

Consensus EPS estimates fall by 64%

Price target increased by 9.1% to US$6.00

Consensus EPS estimates fall by 105%

New minor risk - Profitability

Caremax, Inc. Reports Unaudited Goodwill Impairment for the Three Months Ended September 30, 2023

CareMax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

CareMax, Inc. Announces Resignation of David J. Shulkin as A Member of the Board of Director

Consensus EPS estimates fall by 18%, revenue upgraded

Price target decreased by 11% to US$6.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Revenue Guidance for the Full Year of 2023

CareMax, Inc.'s (NASDAQ:CMAX) Subdued P/S Might Signal An Opportunity

Consensus EPS estimates upgraded to US$0.28 loss, revenue downgraded

Here's What Analysts Are Forecasting For CareMax, Inc. (NASDAQ:CMAX) After Its First-Quarter Results

Caremax, Inc. Reaffirms Full Year 2023 Guidance

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$0.42 loss

Consensus EPS estimates upgraded to US$0.49 loss, revenue downgraded

Consensus revenue estimates fall by 12%

Analysts Have Just Cut Their CareMax, Inc. (NASDAQ:CMAX) Revenue Estimates By 11%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.50

CareMax, Inc. Appoints Ralph De La Torre as Director

Consensus forecasts updated

High number of new and inexperienced directors

CareMax, Inc. (NasdaqGS:CMAX) completed the acquisition of Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC.

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Earnings Guidance for the Full Year 2022

CareMax, Inc. Approves Appointment of Ryan O'quinn as Board of Director

CareMax, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CareMax, Inc., Annual General Meeting, Nov 02, 2022

CareMax: Numbers Are Strong, Compelling Value On Offer

Price target decreased to US$11.10

Consensus estimates of losses per share improve by 14%

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CareMax, Inc. Revises Earnings Guidance for the Full Year 2022

CareMax GAAP EPS of -$0.11 misses by $0.09, revenue of $172.28M beats by $36.85M

CareMax, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$11.00

High number of new and inexperienced directors

CareMax: Steward Health Care Acquisition Highlights Growth Ambitions

CareMax, Inc. (NasdaqGS:CMAX) entered into an agreement to acquire Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC for approximately $135 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen